{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:38:09Z","timestamp":1791506289747,"version":"4.3.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Wenzhou People's Hospital Excellent Youth Talent Project","award":["RC-PH202305 [QN]"],"award-info":[{"award-number":["RC-PH202305 [QN]"]}]},{"name":"Wenzhou People's Hospital Excellent Youth Talent Project","award":["RC-PH202305 [QN]"],"award-info":[{"award-number":["RC-PH202305 [QN]"]}]},{"DOI":"10.13039\/501100018553","name":"Science and Technology Plan Project of Wenzhou Municipality","doi-asserted-by":"publisher","award":["Y20220827"],"award-info":[{"award-number":["Y20220827"]}],"id":[{"id":"10.13039\/501100018553","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-025-04412-0","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T11:03:44Z","timestamp":1759230224000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efgartigimod for treating Guillain-Barr\u00e9 syndrome with poor response to intravenous immunoglobulin: a case report"],"prefix":"10.1186","volume":"25","author":[{"given":"Bai Qi","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sen Xiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao Wen","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping Ping","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"issue":"11","key":"4412_CR1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.202710","volume":"193","author":"A Mirian","year":"2021","unstructured":"Mirian A, Nicolle MW, Budhram A. Guillain-Barr\u00e9 syndrome. CMAJ. 2021;193(11): E378.","journal-title":"CMAJ"},{"issue":"8","key":"4412_CR2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16365","volume":"31","author":"R Bellanti","year":"2024","unstructured":"Bellanti R, Rinaldi S. Guillain-barr\u00e9 syndrome: a comprehensive review. Eur J Neurol. 2024;31(8): e16365.","journal-title":"Eur J Neurol"},{"key":"4412_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1250774","volume":"14","author":"CM Noioso","year":"2023","unstructured":"Noioso CM, Bevilacqua L, Acerra GM, Della Valle P, Serio M, Vinciguerra C, et al. Miller fisher syndrome: an updated narrative review. Front Neurol. 2023;14: 1250774.","journal-title":"Front Neurol"},{"key":"4412_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ensci.2023.100468","volume":"31","author":"HA Zaki","year":"2023","unstructured":"Zaki HA, Iftikhar H, Najam M, Masood M, Al-Marri NDR, Elgassim MAM, et al. Plasma exchange (PE) versus intravenous immunoglobulin (IVIG) for the treatment of Guillain-Barr\u00e9 syndrome (GBS) in patients with severe symptoms: a systematic review and meta-analysis. eNeurologicalSci. 2023;31: 100468.","journal-title":"eNeurologicalSci"},{"issue":"5","key":"4412_CR5","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1055\/s-0043-1775750","volume":"43","author":"R Traub","year":"2023","unstructured":"Traub R, Chaudhry V, Neuroprognostication. Guillain-Barr\u00e9 syndrome. Semin Neurol. 2023;43(5):791\u20138.","journal-title":"Semin Neurol"},{"issue":"6","key":"4412_CR6","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1080\/14737175.2023.2212163","volume":"23","author":"L Magy","year":"2023","unstructured":"Magy L, Frachet S. Therapeutic issues in Guillain-Barr\u00e9 syndrome. Expert Rev Neurother. 2023;23(6):549\u201357.","journal-title":"Expert Rev Neurother"},{"issue":"3","key":"4412_CR7","first-page":"341","volume":"82","author":"YA Heo","year":"2022","unstructured":"Heo YA, Efgartigimod. First Approval Drugs. 2022;82(3):341\u20138.","journal-title":"First Approval Drugs"},{"issue":"8","key":"4412_CR8","doi-asserted-by":"publisher","first-page":"553","DOI":"10.2217\/imt-2022-0298","volume":"15","author":"A Sivadasan","year":"2023","unstructured":"Sivadasan A, Bril V. Clinical efficacy and safety of Efgartigimod for treatment of myasthenia gravis. Immunotherapy. 2023;15(8):553\u201363.","journal-title":"Immunotherapy"},{"issue":"7","key":"4412_CR9","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr.","year":"2021","unstructured":"Howard JF Jr., Bril V, Vu T, Karam C, Peric S, Margania T, et al. Safety, efficacy, and tolerability of Efgartigimod in patients with generalised myasthenia Gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021;20(7):526\u201336.","journal-title":"Lancet Neurol"},{"issue":"6","key":"4412_CR10","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1007\/s00415-024-12321-4","volume":"271","author":"H Zhang","year":"2024","unstructured":"Zhang H, Ma J, Feng Y, Ma H, Liu D, Pang X, et al. Efgartigimod in the treatment of Guillain-Barr\u00e9 syndrome. J Neurol. 2024;271(6):3506\u201311.","journal-title":"J Neurol"},{"key":"4412_CR11","doi-asserted-by":"publisher","DOI":"10.1177\/17562864251314746","volume":"18","author":"S Chen","year":"2025","unstructured":"Chen S, Ou R, Wei Q, Zhao B, Chen X. Sequential administration of efgartigimod shortened the course of Guillain-Barr\u00e9 syndrome: a case series. Ther Adv Neurol Disord. 2025;18: 17562864251314746.","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"4412_CR12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.17843\/rpmesp.2019.361.3729","volume":"36","author":"CV Munayco","year":"2019","unstructured":"Munayco CV, Soto Cabezas MG, Reyes MF, Arica Guti\u00e9rrez JA. Napanga Salda\u00f1a O. [Epidemiology of guillain-barr\u00e9 syndrome in peru]. Rev Peru Med Exp Salud Publica. 2019;36(1):10\u20136.","journal-title":"Rev Peru Med Exp Salud Publica"},{"issue":"11","key":"4412_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16346","volume":"31","author":"RAC Hughes","year":"2024","unstructured":"Hughes RAC. Guillain-barr\u00e9 syndrome: history, pathogenesis, treatment, and future directions. Eur J Neurol. 2024;31(11): e16346.","journal-title":"Eur J Neurol"},{"issue":"3","key":"4412_CR14","first-page":"e57066","volume":"16","author":"S Savithri Nandeesha","year":"2024","unstructured":"Savithri Nandeesha S, Kasagga A, Hawrami C, Ricci E, Hailu KT, Salib K, et al. Treatment efficacy of plasmapheresis versus intravenous Immunoglobulin in Guillain-Barr\u00e9 syndrome management: A systematic review. Cureus. 2024;16(3):e57066.","journal-title":"Cureus"},{"issue":"1","key":"4412_CR15","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/jca.21850","volume":"36","author":"TS Ipe","year":"2021","unstructured":"Ipe TS, Meyer EK, Sanford KW, Joshi SK, Wong ECC, Raval JS. Use of therapeutic plasma exchange for pediatric neurological diseases. J Clin Apher. 2021;36(1):161\u201376.","journal-title":"J Clin Apher"},{"issue":"4","key":"4412_CR16","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S1474-4422(20)30494-4","volume":"20","author":"C Walgaard","year":"2021","unstructured":"Walgaard C, Jacobs BC, Lingsma HF, Steyerberg EW, van den Berg B, Doets AY, et al. Second intravenous immunoglobulin dose in patients with Guillain-Barr\u00e9 syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2021;20(4):275\u201383.","journal-title":"Lancet Neurol"},{"issue":"5","key":"4412_CR17","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41582-021-00467-y","volume":"17","author":"N Papri","year":"2021","unstructured":"Papri N, Islam Z. Guillain-barr\u00e9 syndrome in low-income and middle-income countries: challenges and prospects. Nat Rev Neurol. 2021;17(5):285\u201396.","journal-title":"Nat Rev Neurol"},{"issue":"6","key":"4412_CR18","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40263-024-01090-3","volume":"38","author":"N Alfaidi","year":"2024","unstructured":"Alfaidi N, Karmastaji S, Matic A, Bril V. FcRn inhibitor therapies in neurologic diseases. CNS Drugs. 2024;38(6):425\u201341.","journal-title":"CNS Drugs"},{"key":"4412_CR19","doi-asserted-by":"publisher","first-page":"204062072311728","DOI":"10.1177\/20406207231172831","volume":"14","author":"C Broome","year":"2023","unstructured":"Broome C. Efgartigimod Alfa for the treatment of primary immune thrombocytopenia. Ther Adv Hematol. 2023;14:20406207231172831.","journal-title":"Ther Adv Hematol"},{"key":"4412_CR20","doi-asserted-by":"publisher","DOI":"10.1177\/1756286421997381","volume":"14","author":"MC Dalakas","year":"2021","unstructured":"Dalakas MC, Spaeth PJ. The importance of FcRn in neuro-immunotherapies: from IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors. Ther Adv Neurol Disord. 2021;14: 1756286421997381.","journal-title":"Ther Adv Neurol Disord"},{"issue":"4","key":"4412_CR21","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/CND.0000000000000451","volume":"24","author":"M Jaffry","year":"2023","unstructured":"Jaffry M, Menkes DL, Shaikh A, Mandava K, Kothari O. Neonatal Fc receptor inhibitor therapeutics in neuromuscular disease. J Clin Neuromuscul Dis. 2023;24(4):188\u201398.","journal-title":"J Clin Neuromuscul Dis"},{"issue":"3","key":"4412_CR22","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jaci.2020.07.016","volume":"146","author":"HH Peter","year":"2020","unstructured":"Peter HH, Ochs HD, Cunningham-Rundles C, Vinh DC, Kiessling P, Greve B, et al. Targeting FcRn for immunomodulation: benefits, risks, and practical considerations. J Allergy Clin Immunol. 2020;146(3):479\u2013e491475.","journal-title":"J Allergy Clin Immunol"},{"key":"4412_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1097426","volume":"9","author":"B Fattizzo","year":"2022","unstructured":"Fattizzo B, Motta I. Rise of the planet of rare anemias: an update on emerging treatment strategies. Front Med (Lausanne). 2022;9: 1097426.","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"4412_CR24","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jaci.2020.07.015","volume":"146","author":"DD Patel","year":"2020","unstructured":"Patel DD, Bussel JB. Neonatal Fc receptor in human immunity: function and role in therapeutic intervention. J Allergy Clin Immunol. 2020;146(3):467\u201378.","journal-title":"J Allergy Clin Immunol"},{"issue":"49","key":"4412_CR25","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000040700","volume":"103","author":"J Zhou","year":"2024","unstructured":"Zhou J, Yu W, Ding S, Shi C. Resolution of acute motor axonal neuropathy in a patient after treatment with efgartigimod: a case report. Medicine (Baltimore). 2024;103(49): e40700.","journal-title":"Medicine (Baltimore)"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04412-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-025-04412-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04412-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T11:03:45Z","timestamp":1759230225000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-025-04412-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4412"],"URL":"https:\/\/doi.org\/10.1186\/s12883-025-04412-0","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"24 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the Wenzhou People\u2019s Hospital (KY-202504-028). Written informed consent was obtained from the patient before the publication of this case report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for their personal or clinical details used along with any identifying images to be published in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"403"}}